JNK inhibition shows promise for SMA
Laxman Gangwani outlines the results of a preclinical study showing that JNK inhibition is a promising therapeutic strategy for spinal muscular atrophy, and discusses how this approach might impact the treatment landscape if shown to be beneficial in clinical trials (4:22).
Support for onasemnogene abeparvovec in older SMA patients
Laurent Servais discusses real-world research suggesting that onasemnogene abeparvovec is beneficial in spinal muscular atrophy patients aged 6 months and older, supporting the results of clinical trials involving younger patients (4:13).
Newborn screening linked to earlier diagnosis, treatment of SMA
Laurent Servais talks through the findings of a real-world study showing that newborn screening for spinal muscular atrophy is associated with earlier diagnosis and treatment, and better outcomes, when compared with clinical diagnosis (4:41).
Onasemnogene abeparvovec may be beneficial for bulbar function in SMA type 1
Katlyn McGrattan talks about a post-hoc analysis demonstrating that treatment with onasemnogene abeparvovec can achieve good bulbar function in patients with symptomatic SMA type 1 (3:55).
Olaparib plus abiraterone could be a new first-line treatment option for mCRPC
Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps (3:41).
PROpel: mCRPC patients benefit from add-on olaparib
Author: Shreeya Nanda medwireNews: Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC), show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA. The presenting author – Fred Saad, from Centre Hospitalier de l’Université de Montréal in Quebec, Canada […]
Darolutamide add-on prolongs survival in mHSPC
Author: Laura Cowen medwireNews: Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC), show data from the phase 3 ARASENS trial. Furthermore, the “survival benefit was observed despite a high percentage of patients who received subsequent life-prolonging systemic therapy in […]
ATLANTIS points to maintenance benefit of rucaparib in mUC
Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials (4:47). This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, […]
Novel SERD boosts PFS of patients with ER-positive, metastatic breast cancer
Author: Shreeya Nanda medwireNews: A phase 3 trial has demonstrated a significant progression-free survival (PFS) benefit with the oral selective estrogen receptor degrader (SERD) elacestrant relative to standard of care (SOC) in pretreated patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. Presenting the EMERALD study data at the 2021 San Antonio Breast Cancer Symposium, […]
ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk
Author: Claire Barnard medwireNews: The Janus kinase (JAK) inhibitor tofacitinib is associated with numerically higher rates of major adverse cardiovascular events (MACE) and malignancy than tumor necrosis factor (TNF) inhibitors in people with rheumatoid arthritis (RA) at high cardiovascular (CV) risk, show the ORAL Surveillance results. Five presentations at the ACR Convergence 2021 virtual meeting covered results from […]
